Amyl Co News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article Share this article LIEGE, Belgium, June 3, 2021 /PRNewswire/ -- Amyl Therapeutics ('Amyl'), a preclinical stage biotechnology company developing its amyloid fibrils specific  technology platform named ClariTY for the treatment of all forms of Amyloidosis, today announced that it has successfully closed a €18.3 million Series A financing. The funding round comprises €8.6 million in equity led by Noshaq - a regional Belgian private-public fund - with support from Merieux Participations, Sambrinvest and other private investors; and €9.7 million in non-dilutive funding ...

The round is comprised of: €8.6m in equity led by Noshaq – a regional Belgian private-public fund – with participation from Merieux Participations, Sambrinvest and other private investors; and €9.7m in non-dilutive funding from the DG06 – a key policy-design and implementing body for research and innovation policy in the Walloon region of Belgium. Following the closing of the financing, Dr. Pierre Vandepapelière (Amyl’s Co-Founder, CEO and CMO), Florent Gros (Amyl’s Co-Founder and Chairman), Dr. Valérie Calenda (Managing Partner at Merieux Equity Partners), Kenneth Buckf...